The FDA has approved Promega's OncoMate MSI Dx Analysis System, a PCR-based assay that identifies MSI status in endometrial carcinoma, guiding treatment with KEYTRUDA and LENVIMA. This marks the first Promega companion diagnostic approval, enhancing personalized medicine strategies in oncology.
